Leflunomide

Malignant Solid Neoplasm

City of Hope Medical CenterSmall moleculePhase 1/2Dormant

CCC

48/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 37/ 100
Competitive Position: 81/ 100

Competitive context

1412 Active assets in the Malignant Solid Neoplasm cohort.

Asset / Sponsor	Phase	Rating
Nabiximols Jazz Pharmaceuticals	Phase 3	BBB
Inno-206 M.D. Anderson Cancer Center	Phase 2	BB
Vitamin B6 M.D. Anderson Cancer Center	Phase 4	BB
PROPOFOL Hong Kong Children's Hospital	Phase 4	BB
Rivoceranib Jiangsu HengRui Medicine Co., Ltd.	Phase 4	BB

View all 50 →

Same molecule, other indications

Leflunomide is also rated in:

immunoglobulin G4-related sclerosing diseaseDormant

BB

Indicative ·

69 / 100

central nervous system neoplasmDormant

BB

Indicative ·

64 / 100

plasma cell myelomaDormant

BB

Indicative ·

64 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.